MA41559A - Composé de pyrimidine condensé ou un sel de celui-ci - Google Patents

Composé de pyrimidine condensé ou un sel de celui-ci

Info

Publication number
MA41559A
MA41559A MA041559A MA41559A MA41559A MA 41559 A MA41559 A MA 41559A MA 041559 A MA041559 A MA 041559A MA 41559 A MA41559 A MA 41559A MA 41559 A MA41559 A MA 41559A
Authority
MA
Morocco
Prior art keywords
salt
pyrimidine compound
condensed pyrimidine
condensed
compound
Prior art date
Application number
MA041559A
Other languages
English (en)
Inventor
Hidenori Fujita
Masanori Kato
Isao Miyazaki
Tadashi Shimamura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA41559A publication Critical patent/MA41559A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA041559A 2015-09-08 2016-09-06 Composé de pyrimidine condensé ou un sel de celui-ci MA41559A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015177073 2015-09-08

Publications (1)

Publication Number Publication Date
MA41559A true MA41559A (fr) 2017-12-26

Family

ID=58239818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041559A MA41559A (fr) 2015-09-08 2016-09-06 Composé de pyrimidine condensé ou un sel de celui-ci

Country Status (20)

Country Link
US (4) US10233189B2 (fr)
EP (1) EP3260454B1 (fr)
JP (1) JP6113379B1 (fr)
KR (1) KR102058366B1 (fr)
CN (1) CN108026101B (fr)
AU (1) AU2016319525C1 (fr)
CA (1) CA2996682C (fr)
ES (1) ES2877537T3 (fr)
IL (1) IL257306B (fr)
MA (1) MA41559A (fr)
MX (1) MX390503B (fr)
MY (1) MY192184A (fr)
NZ (1) NZ739893A (fr)
PH (1) PH12017502407A1 (fr)
PL (1) PL3260454T3 (fr)
RU (1) RU2729636C2 (fr)
SG (1) SG11201800135WA (fr)
TW (1) TWI675840B (fr)
WO (1) WO2017043550A1 (fr)
ZA (1) ZA201800218B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
EP3322706B1 (fr) 2015-07-16 2020-11-11 Array Biopharma, Inc. Composés substitués de pyrazolo[1,5-a]pyridines comme inhibiteurs de la kinase ret
HRP20200352T1 (hr) * 2016-02-23 2020-06-12 Taiho Pharmaceutical Co., Ltd. Novi kondenzirani pirimidinski spoj ili njegova sol
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3073375A1 (fr) 2017-08-21 2019-02-28 Taiho Pharmaceutical Co., Ltd. Proteine hybride de proteine dctn1 et de proteine ret
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143994A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
MX2020009234A (es) 2018-04-05 2020-10-12 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CA3199714A1 (fr) * 2020-11-20 2022-05-27 Isao Miyazaki Agent therapeutique antitumoral a migration cerebrale contenant un compose pyrimidine fusionne en tant que principe actif
CA3234317A1 (fr) 2021-10-22 2023-12-14 Wa Xian Methodes et compositions pour traiter une lesion inflammatoire chronique, une metaplasie, une dysplasie et des cancers des tissus epitheliaux

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US5665721A (en) 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
ES2527118T3 (es) * 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
JP5237108B2 (ja) * 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物
EA017865B1 (ru) * 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2011018894A1 (fr) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium
WO2013059740A1 (fr) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Nouvelles molécules de fusion alk et ntrk1 et leurs utilisations
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
WO2014130975A1 (fr) 2013-02-22 2014-08-28 Bastian Boris C Polynucléotides de fusion et polypeptides de fusion associés au cancer, en particulier au mélanome, et leurs utilisations en tant que cibles thérapeutiques et diagnostiques
ES2646019T3 (es) * 2013-05-14 2017-12-11 Nerviano Medical Sciences S.R.L. Derivados de 6-amino-7-deaza-purina, proceso para su preparación y su uso como inhibidores de cinasa
CA2921208C (fr) * 2013-08-12 2018-02-20 Taiho Pharmaceutical Co., Ltd. Compose pyrimidine fusionne ou sel dudit compose
WO2015078417A1 (fr) 2013-11-29 2015-06-04 四川好医生药业集团有限公司 Composé pyrrolopyrimidine et son utilisation dans la préparation d'un médicament hypoglycémiant
JP2015205555A (ja) 2014-04-18 2015-11-19 日立オートモティブシステムズ株式会社 組込制御システム
EP3345907B1 (fr) 2015-09-01 2020-04-22 Taiho Pharmaceutical Co., Ltd. Composées pyrrolo[3,4-d]pyrimidines ou leurs sel
HRP20200352T1 (hr) 2016-02-23 2020-06-12 Taiho Pharmaceutical Co., Ltd. Novi kondenzirani pirimidinski spoj ili njegova sol

Also Published As

Publication number Publication date
US20190092776A1 (en) 2019-03-28
EP3260454A4 (fr) 2018-02-21
WO2017043550A1 (fr) 2017-03-16
US20200270261A1 (en) 2020-08-27
PL3260454T3 (pl) 2021-11-22
KR102058366B1 (ko) 2019-12-23
US11014930B2 (en) 2021-05-25
ES2877537T3 (es) 2021-11-17
ZA201800218B (en) 2019-06-26
US20180009817A1 (en) 2018-01-11
MY192184A (en) 2022-08-05
IL257306A (en) 2018-03-29
CN108026101B (zh) 2020-06-26
EP3260454B1 (fr) 2021-06-09
AU2016319525C1 (en) 2019-07-25
TW201716412A (zh) 2017-05-16
HK1254983A1 (zh) 2019-08-02
US10233189B2 (en) 2019-03-19
JPWO2017043550A1 (ja) 2017-09-07
NZ739893A (en) 2019-07-26
AU2016319525A1 (en) 2018-01-25
RU2729636C2 (ru) 2020-08-11
CA2996682C (fr) 2021-01-12
RU2018112252A (ru) 2019-10-09
PH12017502407B1 (en) 2018-06-25
AU2016319525B2 (en) 2019-01-31
US10787457B2 (en) 2020-09-29
CN108026101A (zh) 2018-05-11
US20200270260A1 (en) 2020-08-27
US11236096B2 (en) 2022-02-01
PH12017502407A1 (en) 2018-06-25
CA2996682A1 (fr) 2017-03-16
JP6113379B1 (ja) 2017-04-12
SG11201800135WA (en) 2018-02-27
KR20180042368A (ko) 2018-04-25
TWI675840B (zh) 2019-11-01
RU2018112252A3 (fr) 2019-10-09
BR112018000698A2 (pt) 2018-09-18
IL257306B (en) 2021-07-29
MX2018002889A (es) 2018-06-18
EP3260454A1 (fr) 2017-12-27
MX390503B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
MA41559A (fr) Composé de pyrimidine condensé ou un sel de celui-ci
ZA201905332B (en) Novel condensed pyrimidine compound or salt thereof
EP3381896A4 (fr) Nouveau composé de biphényle ou un sel de celui-ci
EP3360864A4 (fr) Composé pyrimidine
MA50466A (fr) Nouveau composé de biphényle ou sel de celui-ci
MA45185A (fr) Composé de sulfonamide ou son sel
EP3372604A4 (fr) Composé hétérocyclique condensé
EP3354638A4 (fr) Composé de phtalonitrile
EP3372588A4 (fr) Composé de pyrimidine
EP3381916A4 (fr) Composé pyrimidine condensé ou sel de celui-ci
BR112017017193A2 (pt) compostos herbicidas
EP3438103A4 (fr) Composé de griséofulvine
BR112017023150A2 (pt) compostos herbicidas.
EP3533799A4 (fr) Composé
MA47129A (fr) Sel de composé pipéridine substitué
EP3450436A4 (fr) Composé hétérocyclique condensé
MA43275A (fr) Composé de pyranodipyridine
IL258791A (en) Condensed heterocyclic compound
MA50937A (fr) Nouveau composé isoxazole ou sel de celui-ci
EP3686191A4 (fr) Composé de sulfamide cristallin
EP3315493A4 (fr) Composé de phénylamino pyrimidine ou polymorphe d'un sel de ce dernier
EP3546496A4 (fr) Composé
EP3421542A4 (fr) Composé
BR112017022810A2 (pt) compostos herbicidas.
BR112017022809A2 (pt) compostos herbicidas.